RDP review reports
Last updated on January 31, 2024
In planning the Reference Drug Program (RDP), the Ministry of Health and Drug Benefit Council reviewed many materials relating to RDP drug classes. Many of the materials have proprietary or protected information, or are not readily available. The list below includes only the materials that are freely available to the public.
- Drug Benefit Council Recommendation: Nonsteroidal anti-inflammatory drugs (NSAIDs) (PDF, 157KB) In May 2019, the DBC reviewed the NSAIDs category and made recommendations based on safety, efficacy, and cost-effectiveness
- Drug Benefit Council Recommendation: Reference Drug Program (PDF, 169KB) In September 2014, the DBC reviewed the RDP, including the proposed and existing drug classes
- Histamine2 Receptor Antagonist Review (PDF) - This 2010 review by Provider Synergies LLC is based on published studies of clinical trials and reports on available H2 Blockers and their efficacy and use in patients with gastric and duodenal ulcers, as well as gastroesophageal reflux disease
- Proton Pump Inhibitor (PPI) Drug Class Review (Drug Effectiveness Review Project) - Prepared in 2009 by researchers affiliated with the Oregon Health and Science University and the Drug Effectiveness Review Project, this review compares the benefits and harms of PPIs for the treatment of gastroesophageal reflux disease, H. pylori infection, peptic ulcers, and non-steroidal anti-inflammatory drug-induced ulcers
- PPI Clinical Evidence Review (PDF, 4.26MB) This comprehensive review of clinical evidence reports on the comparative efficacy and safety of PPIs in the treatment of gastroesophageal reflux disease and peptic ulcer disease. This 2014 report is an update of the 2009 PPI Drug Class Review conducted by the Drug Effectiveness Review Project (above)
- PPI Optimal Therapy Report (PDF, 1.05)) - Prepared by the Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) in 2007, this report is a comprehensive review of evidence based literature with recommendations on the optimal use and prescribing of PPIs in the treatment of gastroesophageal reflux disease, dyspepsia, and peptic ulcer disease
- Statins Drug Class Review This Drug Class Review, prepared in 2009 by researchers affiliated with the Oregon Health and Science University and the Drug Effectiveness Review Project, compares the efficacy and safety of statins and statin-combination products in adults and children
- Treatment of Non-Ulcer Dyspepsia in Adults: Common Questions about H2-blockers - Written by the Therapeutics Initiative affiliated with UBC, this 1994 article provides an overview of available H2 Blockers and addresses common questions regarding the treatment of dyspepsia with H2 blockers